New natural history of interferon-β–treated relapsing multiple sclerosis
Article first published online: 19 APR 2007
Copyright © 2007 American Neurological Association
Annals of Neurology
Volume 61, Issue 4, pages 300–306, April 2007
How to Cite
Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zipoli, V., Zimatore, G. B., Di Monte, E., Portaccio, E., Lepore, V., Livrea, P. and Amato, M. P. (2007), New natural history of interferon-β–treated relapsing multiple sclerosis. Ann Neurol., 61: 300–306. doi: 10.1002/ana.21102
- Issue published online: 24 APR 2007
- Article first published online: 19 APR 2007
- Manuscript Accepted: 22 JAN 2007
- Manuscript Received: 30 DEC 2006
- Italian University and Research Ministry. Grant Number: COFIN 2001–2004
- Fondozione Italiana Sclerosi Multipla
To investigate the impact of interferon-beta (IFNβ) on disease progression in relapsing-remitting multiple sclerosis patients.
A cohort of 1,504 relapsing-remitting multiple sclerosis (1,103 IFNβ–treated and 401 untreated) patients was followed for up to 7 years. Cox proportional hazards regression adjusted for propensity score inverse weighting was used to assess the differences between the two groups for three different clinical end points: secondary progression (SP) and irreversible Expanded Disability Status Scale (EDSS) scores 4 and 6. Times from first visit and from date of birth were used as survival time variables.
The IFNβ–treated group showed a highly significant reduction in the incidence of SP (hazard ratio [HR], 0.38, 95% confidence interval [CI], 0.24–0.58 for time from 1st visit; HR, 0.36, 95% CI, 0.23–0.56 for time from date of birth; p < 0.0001), EDSS score of 4 (HR, 0.70, 95% CI, 0.53–0.94 for time from first visit; HR, 0.69, 95% CI, 0.52–0.93 for time from date of birth; p < 0.02), and EDSS score of 6 (HR, 0.60, 95% CI, 0.38–0.95 for time from first visit; HR, 0.54, 95% CI, 0.34–0.86 for time from date of birth; p ≤ 0.03) when compared with untreated patients. SP and EDSS scores of 4 and 6 were reached with significant delays estimated by times from first visit (3.8, 1.7, and 2.2 years) and from date of birth (8.7, 4.6, and 11.7 years) in favor of treated patients. Sensitivity analysis confirmed findings.
IFN-β slows progression in relapsing-remitting multiple sclerosis patients. Ann Neurol 2007;61:300–306